ISB News

The Cancer Paradox

“Paradoxes have been suppressed in cancer research because they challenge paradigms and they’re not good for business,” said Dr. Sui Huang, a cancer researcher and professor at ISB. “But they play a central role in understanding therapy.”

Huang hosted a video Q&A recently where he discussed what he calls the cancer paradox.

“The central paradox in cancer is that treatment often backfires,” he said. Traditional cancer therapies — chemotherapy and radiation — shrink tumors. However, at the same time and despite those beneficial effects, those very same therapies prepare the ground for tumors to recur. “That means cancer therapy can actually promote tumor progression,” he said.

Huang is focused on using the theory of complex systems and applying it to cancer research to better understand the fundamental principles that drive cancer and govern why some cancers respond to therapy while others do not.

Understanding the mechanism of what treatments can backfire will, Huang says, open a new avenue for therapy and treatments. “What we’ve been doing so far is doubling down. We have an ineffective therapy, and then we come up with more powerful ways of killing. It’s one-dimensional linear thinking.”

Instead, he says: “We need to kill the tumor without making it stronger.”

You can watch Huang’s full 18-minute video at the top of this page, or you can watch his answers to individual questions below.

NOTE: If you are watching with no sound, you can enable captions with the “CC” button.

What is the cancer paradox?

Length: 2 minutes, 32 seconds

What are long-held cancer perceptions that should be amended?

Length: 1 minute, 56 seconds

What should someone do if diagnosed with cancer?

Length: 2 minutes, 11 seconds

How does cancer treatment promote perturbation?

Length: 2 minutes, 30 seconds

What is the relationship between inflammation and cancer?

Length: 2 minutes, 24 seconds

How is immunotherapy changing the landscape of cancer treatment?

Length: 2 minutes, 5 seconds

Recent Articles

  • View of the responsive recruitment website and electronic consent platform as seen on mobile phone and desktop devices.

    ISB Builds a Digital Platform for COVID-19 Research Study – And Beyond

    In a multi-institutional study of a highly infectious disease like COVID-19, paperless consent for study participants is critical. One component of the COVID-19 Immune Response Study is a recruitment website with an IRB-approved and HIPAA-compliant electronic consent platform for enrolling patients.

  • Reshaping STEM Education Toward a More Equitable Future for Students

    ISB Assistant Professor Dr. Sean Gibbons recently participated in a virtual event titled “Reshaping STEM Education Toward Equitable Futures for Washington Students.” Panelists shared their insights about how to leverage this complex moment to reshape STEM education toward equity, sustainability, and prosperity for Washington state’s students — especially those furthest from opportunity.

  • Shmulevich-Thorsson

    ISB Researchers Among Recipients of AACR Team Science Award

    The American Association for Cancer Research (AACR) has recognized The Cancer Genome Atlas (TCGA) project with the 2020 AACR Team Science Awards. Award recipients include Dr. Ilya Shmulevich, ISB professor and head of the Shmulevich Lab; ISB senior research scientist Dr. Vésteinn Þórsson; and former Shmulevich Lab members Drs. Brady Bernard and Theo Knijnenburg.